A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
OncoImmunology | November 19, 2020 | Volume: 9 | Issue: 1 | Pages: No page available
10.1080/2162402x.2020.1847846
| PMID 33312760